Medivir, J&J deal

MVIR B will receive E17 million ($24.5 million) in two milestone payments from JNJ's Tibotec Pharmaceuticals Ltd. unit under a 2004 deal to develop MVIR B's HCV protease NS3/4A inhibitors to treat HCV...